Shao Li-Cheng, Jian Hong-Jian, Chen Guang-Hui, Liang Yun-Yi, Huang Wen-Zhu
Third Internal Medical, Foshan Fifth People's Hospital, Foshan 528211, China. E-mail:
Nan Fang Yi Ke Da Xue Xue Bao. 2016 Feb 20;37(2):274-277. doi: 10.3969/j.issn.1673-4254.2017.02.22.
To investigate the recurrence and survival of postoperative patients with differentiated thyroid carcinoma (DTC) aged from 25 to 59 years.
We retrospectively analyzed the clinical data of 36 patients with DTC treated in our hospital from 1996 to 2011, and the recurrence and survival status of the patients were recorded. Kaplan-Meier analysis was carried out to analyze factors that affect the patient's survival.
Nine patients died of recurrence or metastasis, and the interval between the initial surgery and recurrence ranged from 22 to 46 months. The survival time of the 36 patients ranged from 34 to 135 months with a 10-year survival rate of 75.0%. Kaplan-Meier analysis showed that male patients had a significantly shorter mean survival time than female patients (Χ=3.164, P=0.041); the median survival time of patients aged 45-59 years was obviously shorter than that of patients aged 25-44 years (Χ=4.622, P=0.032); the postoperative survival in patients with 131I therapy was significantly longer than those who did not receive the therapy (Χ=4.527, P=0.033), and was not affected by total excision of the thyroid gland (Χ=0.988, P=0.320). No significant difference was found in the median survival of patients in different clinical stages (Χ=2.2132, P=0.167).
In young and middle-aged patients with DTC, postoperative recurrence is the most likely in 2 to 4 years after the surgery. Male patients at 45-59 years of age who do not receive 131I treatment are at high risks of tumor recurrence.
探讨年龄在25至59岁之间的分化型甲状腺癌(DTC)术后患者的复发及生存情况。
回顾性分析我院1996年至2011年收治的36例DTC患者的临床资料,记录患者的复发及生存状况。采用Kaplan-Meier分析法分析影响患者生存的因素。
9例患者死于复发或转移,初次手术至复发的间隔时间为22至46个月。36例患者的生存时间为34至135个月,10年生存率为75.0%。Kaplan-Meier分析显示,男性患者的平均生存时间显著短于女性患者(Χ=3.164,P=0.041);45至59岁患者的中位生存时间明显短于25至44岁患者(Χ=4.622,P=0.032);接受131I治疗患者的术后生存时间显著长于未接受该治疗的患者(Χ=4.527,P=0.033),且不受甲状腺全切除术的影响(Χ=0.988,P=0.320)。不同临床分期患者的中位生存时间差异无统计学意义(Χ=2.2132,P=0.167)。
在中青年DTC患者中,术后复发最可能发生在术后2至4年。45至59岁未接受131I治疗的男性患者肿瘤复发风险高。